CN102215867B - 疾病治疗用组合物 - Google Patents

疾病治疗用组合物 Download PDF

Info

Publication number
CN102215867B
CN102215867B CN200980143326.7A CN200980143326A CN102215867B CN 102215867 B CN102215867 B CN 102215867B CN 200980143326 A CN200980143326 A CN 200980143326A CN 102215867 B CN102215867 B CN 102215867B
Authority
CN
China
Prior art keywords
humanization
antibodies
patient
applications
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980143326.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102215867A (zh
Inventor
弗兰克·奥斯特罗斯
西尔克·艾格纳
克里斯托夫·尤尔克
安德里亚·瓦滕贝格-德曼特
阿纳托利·鲁德涅夫
迈克尔·索尔丹
克里斯托夫·布鲁切尔
本杰明·德尔肯
尚塔尔·祖伯
格雷戈尔·舒尔茨
尼古拉斯·蔡洛特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ogyne Co ltd
Original Assignee
Biotest AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0817810A external-priority patent/GB0817810D0/en
Priority claimed from GB0817811A external-priority patent/GB0817811D0/en
Priority claimed from GB0817809A external-priority patent/GB0817809D0/en
Priority claimed from PCT/EP2009/052809 external-priority patent/WO2009121690A1/en
Priority claimed from PCT/EP2009/052811 external-priority patent/WO2009124815A1/en
Priority claimed from PCT/EP2009/052810 external-priority patent/WO2009112502A1/en
Application filed by Biotest AG filed Critical Biotest AG
Publication of CN102215867A publication Critical patent/CN102215867A/zh
Application granted granted Critical
Publication of CN102215867B publication Critical patent/CN102215867B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200980143326.7A 2008-09-29 2009-08-31 疾病治疗用组合物 Expired - Fee Related CN102215867B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0817810A GB0817810D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817810.5 2008-09-29
GB0817811A GB0817811D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817809A GB0817809D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817811.3 2008-09-29
GB0817809.7 2008-09-29
PCT/EP2009/052809 WO2009121690A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
EPPCT/EP2009/052811 2009-03-10
PCT/EP2009/052811 WO2009124815A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
PCT/EP2009/052810 WO2009112502A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
EPPCT/EP2009/052809 2009-03-10
EPPCT/EP2009/052810 2009-03-10
PCT/EP2009/061210 WO2010034590A1 (en) 2008-09-29 2009-08-31 Composition for treating disease

Publications (2)

Publication Number Publication Date
CN102215867A CN102215867A (zh) 2011-10-12
CN102215867B true CN102215867B (zh) 2017-04-19

Family

ID=41138980

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980143326.7A Expired - Fee Related CN102215867B (zh) 2008-09-29 2009-08-31 疾病治疗用组合物

Country Status (16)

Country Link
US (1) US20110229465A1 (enExample)
JP (2) JP2012504110A (enExample)
KR (1) KR20110061630A (enExample)
CN (1) CN102215867B (enExample)
AU (1) AU2009296078B2 (enExample)
BR (1) BRPI0919489A2 (enExample)
CA (1) CA2738598C (enExample)
CR (1) CR20110226A (enExample)
DK (1) DK2341937T3 (enExample)
ES (1) ES2528419T3 (enExample)
IL (1) IL211904A (enExample)
MX (1) MX2011003335A (enExample)
PT (1) PT2341937E (enExample)
RU (1) RU2531548C2 (enExample)
SG (1) SG194362A1 (enExample)
WO (1) WO2010034590A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
MX2010010027A (es) * 2008-03-13 2011-05-02 Biotest Ag Agente para tratar enfermedad.
RU2539110C2 (ru) * 2008-03-13 2015-01-10 Биотест Аг Способ лечения аутоиммунного заболевания (варианты)
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
GB202017681D0 (en) * 2020-11-09 2020-12-23 T Balance Therapeutics Gmbh Anti-CD4 antibody or fragment thereof for medical use
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083247A1 (en) * 2003-03-21 2004-09-30 Biotest Ag Humanized anti-cd4 antibody with immunosuppressive properties
CN101031305A (zh) * 2004-09-29 2007-09-05 兴和株式会社 类风湿性关节炎的预防和/或治疗药物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
DE69126301T2 (de) * 1990-11-27 1998-01-02 Biogen, Inc., Cambridge, Mass. Hiv-induzierte synzytien blockierender anti-cd-4-antikörper
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ATE204299T1 (de) * 1993-03-05 2001-09-15 Bayer Ag Humane monoklonale anti-tnf alpha antikörper
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
DE19722888A1 (de) * 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
WO2001093908A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
WO2002022212A2 (en) * 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
DE10050935A1 (de) * 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
CA2434972C (en) * 2001-01-16 2010-06-08 Vascular Therapies, Llc Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
NZ528250A (en) * 2001-03-07 2006-09-29 Childrens Medical Center Method to screen peptide display libraries using minicell display
CN1247258C (zh) * 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
ES2392287T3 (es) * 2001-12-04 2012-12-07 Theramab Llc Péptido o proteína que contiene un bucle C'-D de la familia de receptores de la CD28
DE10212108A1 (de) * 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
ME00426B (me) * 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1600164A3 (de) * 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
JP4730733B2 (ja) * 2005-05-02 2011-07-20 国立大学法人京都大学 ４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
US8663634B2 (en) * 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AU2006290433B2 (en) * 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
US20070218062A1 (en) * 2006-03-16 2007-09-20 Genentech, Inc. Methods of treating lupus using CD4 antibodies
EP2262838B1 (en) * 2008-03-13 2016-04-13 Biotest AG Agent for treating disease
RU2539110C2 (ru) * 2008-03-13 2015-01-10 Биотест Аг Способ лечения аутоиммунного заболевания (варианты)
MX2010010027A (es) * 2008-03-13 2011-05-02 Biotest Ag Agente para tratar enfermedad.
ES2351456B1 (es) * 2009-06-24 2011-11-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083247A1 (en) * 2003-03-21 2004-09-30 Biotest Ag Humanized anti-cd4 antibody with immunosuppressive properties
CN101031305A (zh) * 2004-09-29 2007-09-05 兴和株式会社 类风湿性关节炎的预防和/或治疗药物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy;Michael R. Ehrenstein等;《J.Exp.Med.》;20040802;第200卷(第3期);277-285 *

Also Published As

Publication number Publication date
ES2528419T3 (es) 2015-02-09
BRPI0919489A2 (pt) 2015-12-01
AU2009296078A1 (en) 2010-04-01
MX2011003335A (es) 2011-04-27
IL211904A (en) 2016-03-31
HK1154797A1 (en) 2012-05-04
RU2011117293A (ru) 2012-11-10
SG194362A1 (en) 2013-11-29
DK2341937T3 (en) 2015-02-09
JP6154847B2 (ja) 2017-06-28
AU2009296078B2 (en) 2015-08-20
IL211904A0 (en) 2011-06-30
CN102215867A (zh) 2011-10-12
WO2010034590A1 (en) 2010-04-01
KR20110061630A (ko) 2011-06-09
CA2738598C (en) 2017-11-21
PT2341937E (pt) 2015-02-18
US20110229465A1 (en) 2011-09-22
JP2012504110A (ja) 2012-02-16
RU2531548C2 (ru) 2014-10-20
JP2015172060A (ja) 2015-10-01
CA2738598A1 (en) 2010-04-01
CR20110226A (es) 2011-12-05

Similar Documents

Publication Publication Date Title
JP5597553B2 (ja) 疾患治療剤
JP6154847B2 (ja) 疾患治療組成物
JP5795167B2 (ja) 疾患治療剤
JP2023113655A (ja) 小児の障害を処置する方法
CN115944734A (zh) 使用il-17拮抗剂抑制银屑病关节炎患者的结构损伤进展
CN111094339A (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
Caporali et al. Long term treatment of rheumatoid arthritis with rituximab
EP2341937B1 (en) Composition for treating disease
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
JP2022548004A (ja) オマリズマブを使用した治療方法
US20200239562A1 (en) Anti-il-33 therapy for atopic dermatitis
WO2020061571A1 (en) Anti-il-33 antibody for use in treating eosinophilic asthma
HK1154797B (en) Composition for treating disease
CN120202021A (zh) 用于治疗t淋巴细胞介导的疾病的方法
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
TW202405003A (zh) 用於治療ｉｇｇ４相關疾病之方法及組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20191015

Address after: Frankfurt, Germany

Patentee after: Ogyne Co.,Ltd.

Address before: Dreiser, Germany

Patentee before: Biotest Ag

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170419

CF01 Termination of patent right due to non-payment of annual fee